MBNL1-AS1: A Potential Drug Target and Biomarker (G401093)

Target Name: MBNL1-AS1

NCBI ID: G401093

MBNL1-AS1

Other Name(s): MBNL1 antisense RNA 1, transcript variant 1 | MBNL1 antisense RNA 1

MBNL1-AS1: A Potential Drug Target and Biomarker

MBNL1-AS1, also known as MBNL1 antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. MBNL1-AS1 is a key regulator of the myocardial transcriptional landscape and has been shown to play a critical role in the development and progression of cardiovascular diseases, including heart failure, hypertension, and cancer.

The MBNL1 gene is located on chromosome 18q and encodes a protein that is involved in the regulation of mitochondrial function and energy metabolism. MBNL1-AS1 is a splicing variant of the MBNL1 gene that has been shown to have unique functions in various cellular processes. One of the most significant functions of MBNL1-AS1 is its ability to regulate the expression of other genes, including those involved in cell adhesion, migration, and survival.

MBNL1-AS1 has been shown to play a critical role in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that MBNL1-AS1 can promote the growth and survival of cancer cells, and that it can also contribute to the development of cancer-induced cardiomyopathy. In addition, MBNL1-AS1 has been shown to play a role in the regulation of cellular processes that are important for the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in the regulation of cellular processes, MBNL1-AS1 has also been shown to play a critical role in the development and progression of cardiovascular diseases. Studies have shown that MBNL1-AS1 can contribute to the development of cardiomyopathy, a condition in which the heart muscle becomes weak or damaged, and that it can also contribute to the development of other cardiovascular diseases, such as heart failure and hypertension.

The potential drug targets for MBNL1-AS1 are vast, and could include targets related to cell adhesion, migration, and survival, as well as targets related to the regulation of mitochondrial function and energy metabolism. In addition, MBNL1-AS1 could also be used as a biomarker for the diagnosis and prognosis of cardiovascular diseases, such as heart failure, hypertension, and cancer.

Overall, MBNL1-AS1 is a promising drug target and biomarker that has the potential to revolutionize our understanding of cardiovascular diseases. Further research is needed to fully understand the functions of MBNL1-AS1 and to develop effective therapies based on this technology.

Protein Name: MBNL1 Antisense RNA 1

The "MBNL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBNL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets